drugset

drugset / Trial / NCT05659927

Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects

NCT05659927 ↗

Phase 1 Unknown 34 enrolled Shanghai Mabgeek Biotech.Co.Ltd

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine the safety and tolerability of MG-ZG122 in Chinese healthy adult subjects

Timeline

Start: 2023-02-09
Primary completion: 2024-01-26
Completion: 2024-03-23

Publications

Zhang X, Zhu L, Zhang Q, Zheng L, Guo J, Zou Q, Yan R, Qin D, Zhang C, Hu W. Safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of MG-ZG122, a long-acting humanized anti-thymic stromal lymphopoietin mAb, in healthy Chinese: a randomized, double-blind, placebo-controlled, dose-escalation, phase I study. Expert Opin Investig Drugs. 2025 Nov;34(11):943-951. doi: 10.1080/13543784.2025.2581666. Epub 2025 Oct 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MG-ZG122	Monoclonal antibody	52.5 mg	Subcutaneous
Subject	MG-ZG122	Monoclonal antibody	105 mg	Subcutaneous
Subject	MG-ZG122	Monoclonal antibody	210 mg	Subcutaneous
Subject	MG-ZG122	Monoclonal antibody	420 mg	Subcutaneous

Indications